Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer

KIRKLAND, QC, Nov. 7, 2022 /CNW/ - Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio^®, a biosimilar of Avastin^®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal and malignant glioma (WHO Grade IV) - glioblastoma.¹

Read More:  PRNewswireNews - Jornalwebdigital